Véronique Grenier-Caussanel

Title: Innovations by Véronique Grenier-Caussanel in Cancer Treatment

Introduction

Véronique Grenier-Caussanel is an accomplished inventor based in Saint Martin du Fresne, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of humanized antibodies.

Latest Patents

Grenier-Caussanel holds two notable patents related to anti-CXCR4 antibodies. The first patent, titled "Humanized anti CXCR4 antibodies for the treatment of cancer," describes a novel isolated humanized antibody capable of binding to CXCR4. This invention also induces conformational changes in CXCR4 homodimers and/or heterodimers. Specifically, it focuses on hz515H7 antibodies, which are targeted for cancer treatment. The second patent, "Anti CXCR4 antibodies and their use for the treatment of cancer," similarly details an isolated antibody that binds to CXCR4 and induces conformational changes. This patent highlights the 414H5 and 515H7 antibodies and their applications in cancer therapy.

Career Highlights

Grenier-Caussanel is associated with Pierre Fabre Medicament, where he continues to advance his research in the pharmaceutical field. His work has been instrumental in developing therapeutic solutions for cancer patients.

Collaborations

He collaborates with notable colleagues, including Christine Klinguer-Hamour and Alexandra Jouhanneaud, to further enhance the impact of his research.

Conclusion

Véronique Grenier-Caussanel's innovative work in developing anti-CXCR4 antibodies represents a significant advancement in cancer treatment. His contributions are paving the way for new therapeutic options in oncology.